[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adalimumab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adalimumab":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100484620","a-study-of-adalimumab-in-acute-vogt-koyanagi-harada-disease-100484620",false,"NCT05590416","A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease","An Observational Study of Adalimumab in the Treatment of Acute Vogt-Koyanagi-Harada Disease","Inclusion Criteria:\n\n1. Subject is 18 to 70 years of age.\n2. Subjects who do not have previous, active or latent tuberculosis (TB).\n3. Subject must have Vogt-Koyanagi-Harada disease less than one month.\n4. Subject who were previously treated with systemic glucocorticoid less than one week.\n5. Subject meets at least 1 of the following criteria:\n\n1)patients who reject using systemic glucocorticoid because of the long-term side effects. 2)patients with other high-risk or systemic disease were limited by the use of glucocorticoid. 3)patients with a little reparation of retinal detachments after a week treatment with powerful systemic glucocorticoid(≥1mg\u002Fkg\u002Fday).\n\nExclusion Criteria:\n\n1. Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV).\n2. Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.\n3. Subject has previous exposure to anti-tumor necrosis factor (TNF) therapy or any biologic therapy with a potential therapeutic impact on non-infectious uveitis.\n4. Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline visit.\n5. Subject has received intravitreal anti-VEGF therapy within 45 days of the Baseline visit for Lucentis® (ranibizumab) or Avastin® (bevacizumab) or within 60 days of the Baseline visit for anti-VEGF Trap (aflibercept).\n6. Subject has received intravitreal methotrexate within 90 days prior to the Baseline visit.","ALL","18 Years","70 Years",{"count":20,"type":21},15,"ESTIMATED","OBSERVATIONAL","This project is designed to test the hypothesis that adalimumab is clinically useful for patients with acuta Vogt-Koyanagi-Harada disease",[25,26],"Vogt-Koyanagi-Harada Disease","Adalimumab","RECRUITING","2024-07-01",{"date":30,"type":31},"2024-07-03","ACTUAL",{"date":33,"type":31},"2021-06-01",{"date":35,"type":21},"2024-12-30",{"name":37,"class":38},"Tianjin Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100385590","phase-4-a-pilot-study-in-severe-patients-with-takayasu-arteritis-100385590","NCT04300686","A Pilot Study in Severe Patients With Takayasu Arteritis.","A Pilot Study in the Treatment of Severe Patients With Takayasu Arteritis With Tocilizumab and Adalimumab, Based on ECTA Cohort","Inclusion Criteria:\n\n1. age≥14 years old;\n2. active: Kerr score≥ 2;\n3. severe:\n\n   1. Blood pressure \\> 180\u002F110mmHg;\n   2. ≥ 3 branches with the stenotic rate \\> 70% involved;\n   3. high degree of organ insufficiency: NYHF III\\~IV; eGFR (MRDR) 15\\~ 60ml\u002Fmin;\n\nExclusion Criteria:\n\n1. Severe organ insufficiency;\n2. Acute or chronic active infections including tuberculosis, hepatitis virus, etc.;\n3. Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease;\n4. malignant tumors;\n5. history of severe drug allergy;\n6. successive twice relapse occurs even after the intervention adjustment ( for the benefits of patients)","14 Years","100 Years",{"count":50,"type":21},40,"INTERVENTIONAL",[53],"PHASE4","Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.",[56,57,26,58],"Takayasu Arteritis","Tocilizumab","Treatment",[56,57,26,60],"treatment","2021-08-07",{"date":63,"type":31},"2021-08-10",{"date":65,"type":31},"2020-03-01",{"date":67,"type":21},"2023-12-31",{"name":69,"class":38},"Shanghai Zhongshan Hospital"]